Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

There is currently no effective therapeutic to stabilize or reverse the cognitive impairment
of Alzheimer's Disease (AD) and related dementias. Clinical trials with drugs have been
unsuccessful because the wrong therapeutic target/species were selected, because drugs have
great difficulty traversing the blood-brain barrier and getting into neurons, and/or because
drugs largely have only a single mechanism of action. Since ever-increasing experimental
evidence indicates that the toxic forms of both beta-amyloid and tau are the soluble
"oligomeric" species of these two proteins, therapeutics to disaggregate these oligomers
within neurons represent perhaps the best chance for attaining cognitive benefit in AD
patients.

Pre-clinical studies performed by the Sponsor and his collaborators have demonstrated that AD
transgenic mice treated daily with electromagnetic waves in the radiofrequency (RF) range are
protected from cognitive impairment or show a reversal of pre-existing cognitive impairment.
These cognitive benefits appear to be due primarily to two complimentary mechanisms: 1)
disaggregation of toxic protein oligomers within neurons, and 2) mitochondrial enhancement to
increase energy metabolism. Moreover, no deleterious effects of treatment over many months
have been observed in these pre-clinical studies.

In order to provide similar treatment to mild/moderate Alzheimer's patients clinically,
NeuroEM Therapeutics has developed a unique head device that provides electromagnetic (RF)
treatment to the entire human forebrain at levels similar to those that provided cognitive
benefits in pre-clinical studies. Using the MemorEM 1000 head device in the present Phase I
trial, AD patients receive twice daily 1-hour treatments in-home, as administered by their
caregiver. The device allows for the patient to have complete mobility for moving throughout
their home.

A comprehensive array of markers will be analyzed both during and following the 2-month
treatment period, with baseline (pre-treatment) values serving as controls. Cognitive safety
and efficacy will be evaluated using a variety of cognitive assessments including ADAS-cog
(Primary), and secondary cognitive measures including ADCS-ADL, Rey AVLT, Trails A & B, Digit
span, and clock draw tasks. Treatment effects on brain energy metabolism will be determine by
FDG-PET scans, while treatment effects on brain functional connectivity will be determined
through both resting state MRI and Diffusion Tensor Imaging. Also being assessed are the
effects of treatment on various beta-amyloid and tau protein species (e.g., monomers,
oligomers) in both blood and CSF. Safety of the treatment will be monitored by regular
Adverse Events Assessment, physiologic monitoring, and patient daily diaries maintained by
the caregiver.

Expected Results: The investigators expect that 2-months of daily electromagnetic (RF)
treatment will not present any significant side effects or safety issues. The investigators
further expect that cognitive measures will be stable and/or improve by the end of treatment.
In addition, the investigators anticipate that brain functional connectivity may be improved
and that enhanced brain metabolism (FDG-PET) will occur. Changes in blood/CSF levels of
various beta-amyloid and tau species are also anticipated.

Inclusion Criteria:

- Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to
the National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.

- MMSE score 16 to 26

- Physical clearance for study participation as evaluated by the clinician.

- Caregiver (spouse, family member, etc.) who agrees to and is capable of taking care
and being responsible for the participation of the patient in the study (keeping a
diary of health measures they collect on the patient at home, logging the patient's
condition daily, and assuming responsibility for administering daily in-home
treatment). Caregiver to have non-impaired mental abilities and normal motor skills,
as determined by the investigators at screening. The definition of caregivers for this
study is adults providing unpaid care to relatives or friends to help them take care
of themselves in such activities as managing finances, shopping, preparing meals, and
going to doctor appointments.

- Agreement to participate in approximately 10 weeks during the study.

- Normal to near-normal vision and hearing with correction as needed (e.g. corrective
lenses, hearing aid).

- Fluent in English

- Minimum of 8th grade education

- Head circumference between 53 - 58 cm (to minimize variability in head antenna
locations)

- If medicated for AD, then use of cholinesterase inhibitors and/or memantine for at
least 3 months, on stable dose for at least 60 days prior to screening, and
maintenance on that dose for the period of this study.

- All other non-AD medications must be stable for a period of 4 weeks prior to screening

Exclusion Criteria:

- CDR Global Score of 0, 0.5 or 3

- Severe agitation

- Mental retardation

- Unstable medical condition

- Use of benzodiazepines or barbiturates 2 weeks prior to screening

- Participation in a clinical trial with any investigational agent within 6 months prior
to study enrollment and no history of immunotherapy research participation

- History of Epileptic Seizures or Epilepsy

- Patients with major depression (not controlled with medication), bipolar disorder or
psychotic disorders or any other neurological or psychiatric condition (whether now or
in the past). The investigator will obtain this information from available patient
medical records, history provided by the patient and caregiver, interview, and
neurological exam.

- Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more
than one year and or in remission less than 3 years) or severe sleep deprivation

- Patients with metal implants in the head, (i.e. cochlear implants, implanted brain
stimulators, aneurysm clips) with the exception of metal implants in mouth

- Patients with vitamin B12 deficiency, abnormal thyroid function, or personal history
of either any clinically defined medical disorder or any clinically defined
neurological/psychiatric disorder (other than AD), including (but not limited to):,
stroke, brain lesions, , cerebrovascular condition, other neurodegenerative disease,
significant head trauma (loss of consciousness greater than half an hour, or related
anterograde amnesia), multiple sclerosis; or personal history of previous neurosurgery
or brain radiation

- Patients with any signs or symptoms of increased intracranial pressure, as determined
in a neurological exam.

- Patients with demonstrated brain micro-hemorrhages at screening

- Patients with a score of 4 or higher on the Hachinski Test

- Patients with a score of 2 or less on the Global Deterioration Scale

- Patients with hypertension that is unresponsive to anti-hypertensive medications

- Patients with a history of migraine headaches occurring more than once a month

- Patients with a history of cancer within the last 3 years

- Patients chronically taking anticoagulants or anti-platelets (at discretion of
Principal Investigator)

- Pregnant women and women who have the ability to become pregnant

- Patients with compressed hair thickness of more than 5mm (which could increase
distance between head antennas and the scalp).

- Cardiac pacemakers

- Implanted medication pumps

- Intracardiac lines

- Significant heart disease